We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery Sign Multi-Year Technology Access Agreement with Genentech
News

Horizon Discovery Sign Multi-Year Technology Access Agreement with Genentech

Horizon Discovery Sign Multi-Year Technology Access Agreement with Genentech
News

Horizon Discovery Sign Multi-Year Technology Access Agreement with Genentech

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery Sign Multi-Year Technology Access Agreement with Genentech"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Through an additional agreement, Horizon Discovery has provided open access to its 150+ strong X-MAN™ cell-line library to Genentech, Inc., a wholly-owned member of the Roche Group,  for a period of up to three years. Genentech will utilize the in-licensed cell-line panels in its oncology research programs. The relationship builds on the previous business agreements between the companies.

X-MAN ‘Mutant And Normal’ cell-lines provide researchers with a consistent source of human cell-types that harbor a specific cancer causing gene (or genes), plus a matched reference normal cell as a control; enabling the rational development of novel drugs or treatments that more effectively target specific patient populations.

Dr Paul Morrill, Business Development Director of Horizon says “Genentech have been a model early-adopter and pivotal to Horizon validating its GENESIS™ and X-MAN technology in an industrial setting. The relationship has yielded some exciting findings which are being translated into publications that will help others striving to develop targeted cancer agents. We believe the new open-access deal with Genentech will further enable Horizon to continue to supply first-in-class, in-vitro models of human cancer for Rx and Dx applications.”

Through its agreements, Genentech pays Horizon undisclosed up-front, milestone and renewal fees.
Advertisement